Common Contracts
5 similar Co-Development and Co-Commercialization Agreement contracts by Adaptimmune Therapeutics PLC
Agreement covers the co-development and co-commercialization of up to three T-cell therapies -Co-Development and Co-Commercialization Agreement • November 29th, 2022
- Astellas will pay Adaptimmune an upfront payment, research funding, development and commercial milestones, and royalties on net sales on co-commercialized products -
Agreement covers the co-development and co-commercialization of up to three T-cell therapies -Co-Development and Co-Commercialization Agreement • December 15th, 2021
- Astellas will pay Adaptimmune an upfront payment, research funding, development and commercial milestones, and royalties on net sales on co-commercialized products -
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co- Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell TherapiesCo-Development and Co-Commercialization Agreement • February 3rd, 2021
- Agreement leverages Astellas’ Universal Donor Cell Platform and Adaptimmune’s stem-cell derived allogeneic T-cell platform -
Agreement covers the co-development and co-commercialization of up to three T-cell therapies -Co-Development and Co-Commercialization Agreement • January 14th, 2020
TOKYO, PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), through its wholly-owned subsidiary Universal Cells, Inc, and Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that they have entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co- Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies - Agreement covers the co-development and co-commercialization of up to three T-cell therapies - - Agreement...Co-Development and Co-Commercialization Agreement • January 14th, 2020 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
TOKYO and PHILADELPHIA, PA, OXFORDSHIRE, United Kingdom, January 14, 2020 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), through its wholly-owned subsidiary Universal Cells, Inc, and Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that they have entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.
